



NOTICE

“NOTICE” is hereby given that the 17th Annual General Meeting of Biodeal Pharmaceuticals Private Limited (CIN: U00304HP2005PTC029451) will be held on **Thursday, 29th day of September, 2022** at 11:00 am at Village SainiMajra, Nalagarh-Ropar Road, Nalagarh, Solan, Himachal Pradesh-India, Registered office of the Company to transact the following businesses as:

ORDINARY BUSINESS

Item No. 1 :

To receive, consider and adopt the audited financial statements of the company for the financial year ended on 31st March, 2022 and the report of board of directors and auditors' thereon. To consider and if thought fit, to pass, with or without modification(s), the following resolution as Ordinary Resolution:

“RESOLVED THAT the audited financial statements of the Company for the financial year ended March 31, 2022 and the reports of the board of directors and auditors thereon laid before this meeting, be and are hereby considered and adopted.”

Item No. 2 : To take note of the appointment of Statutory Auditors

To consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 139 and all other applicable provision of the Companies Act 2013, read with Rule 3(7) of the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), the members hereby take note of the appointment of M/s Joshi Vishal & Associates, Chartered Accountants, Chandigarh (Firm Registration No- 016437N), as the Statutory auditor of the Company for financial year from 2019-20 to 2023-24 and to fix their remuneration as may be decided by the Board of Directors in consultation with the Statutory Auditors' of the Company”.

SPECIAL BUSINESS

Item No. 3 : Ratification of remuneration to Cost Auditors for financial year 2022-23


To consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

To ratify the remuneration payable to the Cost Auditor appointed by the Board of Directors of the Company for the financial year 2022-23 pursuant to Section 148 and all other applicable provisions of Companies Act, 2013, by passing with or without modification(s), the following resolution as Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 148(3) of the Companies Act, 2013 read with Rule 14 of Companies (Audit and Auditors) Rules, 2014 and other applicable provisions of the Companies Act, 2013, the remuneration of Rs. 98,100/- (Rupees Ninety Eight Thousand One Hundred Only) excluding applicable Tax payable to M/s. JSN & Co., Cost Accountants, Delhi for conducting cost audit of the Company for the financial year 2022-23, as approved by the Board of Directors of the Company, be and is hereby ratified.”

**For and on behalf of the Board of Directors
For Biodeal Pharmaceuticals Private Limited**

**Place: Nalagarh
Date: 25.08.2022**

Anurag Kumar 
Director
DIN:08598700
**Address: House No 793, Sector 3-d,
Bokaro Steel City, Bokaro, Jharkhand-827001**

NOTES:

1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ALSO ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF / HERSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY. PROXIES IN ORDER TO BE EFFECTIVE MUST BE RECEIVED BY THE COMPANY AT ITS REGISTERED OFFICE NOT LATER THAN 48 HOURS BEFORE COMMENCEMENT OF THE MEETING. PROXIES SHALL NOT HAVE ANY RIGHT TO SPEAK AT THE MEETING. IN CASE A PROXY ACTS FOR A MEMBER HOLDING MORE THAN 10% OF TOTAL SHARE CAPITAL CARRYING VOTING RIGHTS CANNOT ACT AS PROXY FOR ANY OTHER MEMBER.
2. A PERSON CAN ACT AS PROXY ON BEHALF OF MEMBERS NOT EXCEEDING FIFTY (50) AND HOLDING IN THE AGGREGATE NOT MORE THAN TEN PERCENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY.
3. The Proxy-holder shall prove his/her identity at the time of attending the Meeting.
4. Documents relating to any of the items mentioned in the notice are open for inspection at the registered office/Corporate office of the company on any working days during business hours and shall also be available at the meeting.
5. Only bonafide members of the company whose names appear on the register of members/proxy holders, in possession of valid attendance slips duly filled and signed will be permitted to attend the meeting. The company reserves its right to take all steps as may be deemed necessary to restrict non-members from attending the meeting.
6. Members are requested to inform the company immediately, if any change in their address.
7. A Route Map along with Prominent Landmark for easy location to reach the venue of Annual General Meeting is annexed as *Annexure I* with the notice of Annual General Meeting.
8. The Members who desire to inspect the proxy register must send a request at least three days before the meeting. The inspection may be made at business hour during the 24 hours before the meeting and till the conclusion of the meeting.

ATTENDANCE SLIP

Registered Folio no. No. of shares held.	
Name and Address of the Shareholder(s)	

1. I hereby certify that I am a registered shareholder/proxy for the registered Shareholder of the Company and hereby record my presence at the 17th Annual General Meeting of the Company on Thursday, 29th day of September, 2022 at Village SainiMajra, Nalagarh-Ropar Road, Nalagarh, Solan, Himachal Pradesh-India, the registered office of the Company at 11.00 am.

2. Signature of the Shareholder / Proxy Present:



Member's/Proxy's name in Block Letters

Member's/Proxy's Signature

3. Shareholder / Proxy Holder wishing to attend the meeting must bring the duly signed Attendance Slip to the meeting.

4. Shareholder/Proxy Holder attending the meeting is requested to bring his / her copy of the Annual Report.

Note: Please fill this attendance slip and hand it over at the entrance of the hall.

Form No. MGT-11

Proxy form

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: U00304HP2005PTC029451

Name of the Company: Biodeal Pharmaceuticals Private Limited

Registered office: Village SainiMajra, Nalagarh-Ropar Road, Nalagarh, Solan, Himachal Pradesh-India

Name of the Member(s): Registered address: E-mail Id: Folio No/ Clint Id: DP ID:
--

I/ We being the member of, holding.....shares, hereby appoint:

1. **Name:**

Address:

E-mail Id:

Signature:, or failing him

2. **Name:**

Address:

E-mail Id:

Signature:,

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at Annual General Meeting of members of the Company, to be held on **Thursday, 29th day of September, 2022** at Village SainiMajra, Nalagarh-Ropar Road, Nalagarh, Solan, Himachal Pradesh-India, the Registered Office of the Company at 11.00 am and at any adjournment thereof in respect of such resolutions as are indicated below:

Resolution No.

Ordinary Buisness:

1. To receive, consider, approve and adopt the audited financial statements of the company for the financial year ended on March 31, 2022 along with the directors' and auditors' report thereon.

2. To take note of Appointment of Statutory Auditors and to fix their remuneration

Special Business:

3. Ratification of remuneration to Cost Auditors for financial year 2022-23

Signed this day of..... 2022

Signature of Shareholder

Signature of Proxy holder(s)

Affix Revenue Stamp


Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the time fixed for commencement of the meeting.

Annexure-I

Route Map and Prominent Landmark:-

Rout Map Link :-<https://goo.gl/maps/Zrb4ygeAUy9UErE66>

Google Maps Biodeal Pharmaceuticals Pvt . Ltd.



Map data ©2022 10 km



EXPLANATORY STATEMENT
(Pursuant to Section 102 of the Companies Act, 2013)

In conformity with the provisions of section 102 of the Companies Act, 2013, the following resolution sets out the material facts relating to the business under Item No. 3.

Item No. 3 : Ratification of remuneration to Cost Auditors for financial year 2022-23

The Board has approved in its meeting held on 25.08.2022, the appointment of M/s. JSN & Co., Cost Accountants, Delhi, at a remuneration of Rs. 98,100/- (Rupees Ninety Eight Thousand One Hundred Only) excluding applicable taxes to conduct the Cost Audit of the Company for the financial year 2022-23. In accordance with the provisions of Section 148 (3) of the Companies Act, 2013 read with Rule 14 of Companies (Audit & Auditor Rules), 2014, the remuneration payable to the Cost Auditor is required to be ratified by the members of the Company.

None of the Directors, Key Managerial Personnel of the Company or their relatives is in any way, concerned or interested, financially or otherwise, in this resolution.

The Board of Directors recommends the Ordinary Resolution for your approval.

For and on behalf of the Board of Directors
For Biodeal Pharmaceuticals Private Limited

Place: Nalagarh
Date: 25.08.2022

Anurag Kumar
Director

DIN:08598700

Address: House No 793, Sector 3-d,
Bokaro Steel City, Bokaro, Jharkhand-827001



BOARD REPORT

To,
The Members,

Your Directors have pleasure in presenting their 17th Annual Report on the business and operations of the Company and the accounts for the Financial Year ended March 31, 2022.

1. Financial summary or highlights/Performance of the Company

The Financial highlights of the performance of the Company for the Year under review is mentioned below:

Particulars	(In Rupees)	
	2021-22	2020-21
Total Revenue	72,06,15,737	53,45,39,275
Total Expenditure	65,85,22,636	48,50,70,366
Profit before tax	6,20,93,101	4,94,68,909
Less: Current Tax	82,61,406	-
Less: Deferred Tax	85,44,075	1,24,50,334
Profit after tax	4,52,87,620	3,70,18,575

2. State of Company's affairs and future outlook

The Company is into the business to manufacture, produce, process, prepare, sale, import, export and deal in all kinds of commercial activities related to pharmaceuticals and chemical products of medicaments in all its branches.

During the period under review, the Company earned net profit after tax of Rs. 4,52,87,620/- (Rupees Four Crore Fifty Two Lakh Six Hundred Twenty Only) as compared to profit in the previous financial Year of Rs. 3,70,18,575 /- (Rupees Three Crore Seventy Lakh Eighteen Thousand Five Hundred Seventy Five Only). The gross revenue of the company for the Financial Year 2021-2022 is Rs. 72,06,15,737/- (Rupees Seventy Two Crore Six Lakh Fifteen Thousand Seven Hundred Thirty Seven Only) as compared to gross revenue of Rs. 53,45,39,275/- (Rupees Fifty Three Crore Forty Five Lakh Thirty Nine Thousand Two Hundred Seventy Five Only) in the previous Financial Year. Your directors expect that the Company will achieve new heights in the coming years.

3. Change in the nature of business, if any

During the year under review, there have not been any changes in the nature of business of the Company.

4. Details of Application / any proceedings pending under the Insolvency and Bankruptcy Code, 2016

During the financial year under review, neither any applications was made nor any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016).

5. Details of difference between amount of the Valuation done at the time of One Time Settlement and the Valuation done while taking Loan from the Banks or Financial Institutions along with the reasons thereof

As Company has not done any one time settlement during the year under review hence no disclosure is required.

6. Amount Transferred to Reserve

The Company has transferred the amount of Rs. 4,52,87,620/- being the profit for the current year to the general reserve in the balance sheet during the financial year ended 31st March, 2022.

7. Dividend

The Board of Directors of the Company do not recommend any dividend for the financial year under review.

8. Deposits

The required details relating to deposits, covered under Chapter V of the Companies Act, 2013: –

- (a) Accepted during the year – the Company has not invited or accepted deposits; NIL
- (b) Remaining unpaid or unclaimed as at the end of the year – as the Company has not accepted deposits, there are no remaining unpaid or unclaimed deposits - NIL
- (c) Whether there has been any default in repayment of deposits or payment of interest thereon during the year and, if so, the number of such cases and the total amount involved - NA
 - i. At the beginning of the year - NIL
 - ii. Maximum during the year -NIL
 - iii. At the end of the year - NIL

9. Web address of the Company

The company is using its www.biodealpharma.com web address.

10. Material Changes and Commitments, if any, affecting the Financial Position of the Company

There have not been any material changes and commitments during the financial year which may affect the financial position of the Company.

11. Changes in Capital Structure of the Company

There is no change in the authorized & Paid up share capital during the period under review.

The Authorized Share Capital of the Company is Rs. 250,000,000/- (Rupees Twenty Five Crores only) divided into 25,000,000 (Two Crore Fifty Lacs only) Equity Shares of Rs. 10/- each.

The Paid up Share Capital of the Company is Rs. 250,000,000/- (Rupees Twenty Five Crores only) divided into 25,000,000/- (Two Crore Fifty Lacs only) Equity Shares of Rs. 10/- each.

Other mandatory disclosures as per Companies Act, 2013 are provided hereunder:

Issue of Equity Shares with Differential Rights:—

During the financial year ended 31st March, 2022, the Company has not issued any Equity Shares with Differential Rights.

Issue of Employee Stock Options:—

During the financial year ended 31st March, 2022, the Company has not issued any Employee Stock Options as stated in Section 62(1)(b) of the Companies Act, 2013 and Rule 12(9) of Companies (Share Capital and Debenture Rules, 2014).

Issue of Sweat Equity Shares:—

During the financial year ended 31st March, 2022, the Company has not issued any sweat equity shares as specified in Section 54 of the Companies Act, 2013 and Rule 8(13) of Companies (Share Capital and Debenture Rules, 2014).

12. Details of Subsidiary, Joint Venture or Associates

The Company does not have any Subsidiary, Joint venture or Associate Company.

13. Extract of Annual Return in Form MGT - 9

The extract of annual return as required under section 92(3) of the Companies Act, 2013 (*Act) for the year under review is made available in the prescribed Form MGT - 9, as **Annexure-II**.

14. Number of Board Meetings

The Board met 16 times during the financial year 2021-22 under review. The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013.

The dates on which the Meetings of the Board of Directors were held during the reporting period and directors who attended the same is given below:

S. No	Date of Board Meetings	Board Strength	Directors present in Board Meeting		
			Mr. Anurag Kumar	Mr. DevDatt*	Mr. Subodh Prasad Singh**
1	01.04.2021	3	Present	Present*	Present
2	06.04.2021	2	Present	Present	NA
3	15.04.2021	2	Present	Present	NA
4	03.07.2021	2	Present	Present	NA
5	05.08.2021	2	Present	Present	NA
6	14.09.2021	2	Present	Present	NA
7	15.09.2021	2	Present	Present	NA
8	20.09.2021	2	Present	Present	NA
9	22.09.2021	2	Present	Present	NA
10	11.10.2021	2	Present	Present	NA
11	18.10.2021	2	Present	Present	NA
12.	10.11.2021	2	Present	Present	NA
13.	15.11.2021	2	Present	Present	NA
14.	30.12.2021	2	Present	Present	NA
15.	13.01.2022	2	Present	Present	NA
16.	15.03.2022	2	Present	Present	NA

* Mr. Dev Datt, appointed as Whole Time Director on 01.04.2021

** Mr. Subodh Prasad Singh, Director resigned on 02.04.2021

15. Change in the Board/Management of the Company

During the year under review, Mr. DevDatt was appointed as Whole Time Director on 1st day of April, 2021, the management welcomes him on the Board of Directors of the company.

Mr. Subodh Prasad Singh, Director resigned from the company on 2nd day of April, 2021. The Board placed on record its whole-hearted appreciation for the invaluable contribution made by Mr. Subodh Prasad Singh during his tenure as Director of the Company.

16. Particulars of Loan, Guarantees and Investments under Section 186

Loans, Investments and guarantee Covered under Section 186 of the Companies Act, 2013 form the part of the notes to the financial statements provided in this Annual report.

17. Particulars of Contracts or Arrangements with Related Parties

During the period there are contracts or arrangements entered with related parties referred to in the provision of the Section 188(1) of the Companies Act, 2013 which are attached as **Annexure III** to this report.

18. Loan from Directors, Relative of Directors & Other individuals

During the year under review, the loan taken from Director forms the part of the notes to the financial statements.

19. Auditors

The members are informed that pursuant to the provisions of Section 139 read with the Companies (Audit and Auditors) Rules, 2014; M/s Joshi Vishal & Associates, (Chartered Accountants), Chandigarh have been appointed as Statutory Auditor of the Company, who shall hold office till the conclusion of Annual General Meeting to be held in the Calendar year 2024.

20. Auditors' Report

The observations of Auditor's in their report read with relevant notes are self-explanatory and do not require any further clarification and explanation.

21. Disclosure about Maintenance of Cost Records

Your Company has appointed M/s JSN & CO. as Cost Auditor of the Company for financial year 2021-22 and re-appointed for the financial year 2022-23.

Your Company is maintaining Cost Accounting Records as prescribed under the Companies (Cost Records and Audit) Rules, 2014, specified by the Central Government under sub-section (1) of Section 148 of the Companies Act, 2013.

22. Secretarial Audit Report

Your Directors wish to inform that the Secretarial audit was not applicable to the company during the Financial Year 2021-22.

23. Internal Audit & Controls

As per the provisions of Section 138 of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014, the provisions of Internal Audit are not applicable on the Company for the year under review.

24. Statement in respect of adequacy of Internal Financial Control with reference to the Financial Statements

The Company has an adequate internal financials control with reference to the financial statement. During the year hence no reportable material weakness in the design or operations were observed.

25. Conservation of Energy, Technology, Absorption, Foreign Exchange Earnings and Outgo

The information relating to the Conservation of energy, technology absorption and foreign exchange earnings and outgo as required under Rule 8(3) of the Companies (Accounts) Rules, 2014 is detailed herein below :

A. CONSERVATION OF ENERGY

- 1) the steps taken or impact on conservation of energy: NIL
- 2) the steps taken by the company for utilizing alternate sources of energy: NIL
- 3) the capital investment on energy conservation equipment's: NIL

B. TECHNOLOGY ABSORPTION

- 1) the efforts made towards technology absorption: NIL
- 2) the benefits derived like product improvement, cost reduction, product development or import substitution: NIL
- 3) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year): NIL
- 4) the expenditure incurred on Research and Development: NIL

C. FOREIGN EXCHANGE EARNINGS AND OUTGO

On accrual basis, following is the relevant information:

S. No.	Particulars	As at 31.03.2022 Amount (Rs.)	As at 31.03.2021 Amount (Rs.)
1	Expenditure in Foreign Currency	7,04,26,298/-	3,89,24,024/-
2	Earning in Foreign Currency	8,76,74,406/-	8,66,27,398/-

26. Risk Management Policy

In today's economic environment, Risk Management is a very important part of business. The main aim of risk management is to identify, monitor and take precautionary measures in respect of the events that may pose risks for the business. The Company has adequate risk management plans and processes in place that commensurate with the size of its business operations. The Management of your Company has devised proper strategies to apprehend risks, take timely actions to mitigate them and convert them to opportunities for the Company.

27. Declaration by Independent Directors

Since, the Company is a Private Limited Company, the provisions of Section 149 of the Companies Act, 2013 and the rules made there under, relating to appointment of Independent directors are not applicable to the Company.

28. Audit Committee

Since, the Company is a Private Limited Company, the provisions of Section 177 of the Companies Act, 2013 read with Companies (Meetings of its Board and its Power) Rules, 2014, to constitute an Audit Committee are not applicable to the Company.

29. Nomination and Remuneration Committee

Since, the company is not covered under the provisions of Section 178 of the Companies Act, 2013, hence it is not required to constitute the Nomination and remuneration committee.

30. Establishment of Vigil Mechanism

The provisions of Section 177 of the Companies Act, 2013 and the rules made thereunder, in relation to establishment of vigil mechanism are not applicable to the Company for the year under review.

31. Disclosure of Corporate Social Responsibility (CSR)

Pursuant to the provisions of Section 135 of the Companies Act 2013, every Company having net worth of Rupees Five Hundred Crore or more, or turnover of Rupees One Thousand Crore or more or a net profit of Rupees Five Crore or more during any financial year shall constitute a Corporate Social Responsibility Committee of the Board consisting of three or more directors, out of which at least one director shall be an Independent Director. Since the provisions of section 135 of the Companies Act, 2013 were not applicable on the company for the period ended as at March 31, 2022, the company has not developed or implemented any policy on Corporate Social Responsibility and subsequently no initiatives taken during the year.

32. Details of significant & material orders passed by the regulators or courts or tribunal

There has been no order passed by any regulators or courts or tribunal which impacts the going concern status and company's operations in future.

33. Disclosures under Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013

The Company has zero tolerance for Sexual Harassment at workplace and has adopted and laid down a policy on prevention of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made thereunder. The policy aims to provide protection to employees at the workplace and prevent redress complaints of sexual harassment and for matters connected or incidental thereto, with the objective of providing a safe working environment, where employees feel secure. The Internal complaint committee known as Prevention of Sexual Harassment (POSH) Committee has also been formed by the Directors to inquire into the complaints of sexual harassment and recommend the appropriate actions, if any.

Your company is fully committed to protect the rights of any women, of any age, whether employed or not, who alleges to have been subjected to any act of sexual harassment within the Company's premises. Your Company provides a safe and healthy work environment.

However, there were no cases reported otherwise, during the year ended on March 31, 2022 of sexual harassment.

34. Statement of Compliances of applicable Secretarial Standards on board and general meeting:

The Company has complied with applicable Secretarial Standards issued by the Institute of Company Secretaries of India, during the Financial Year under review.

35. Statement of Particulars of Employees

Pursuant to Rule 5(2) & (3) of The Companies (Appointment & Remuneration of Managerial Personnel) Rules, 2014 every listed Company shall disclose the details about its employees. Hence this provision is not applicable to our Company.

36. Directors' Responsibility Statement

In accordance with the provisions of Section 134(5) of the Companies Act 2013, your directors confirm that:

a) in the preparation of the annual accounts for the financial year ended 31st March, 2022, the applicable accounting standards had been followed along with proper explanation relating to material departures;

- b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2022 and of the profit /loss of the Company for that period;
- c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) the directors had prepared the annual accounts on a going concern basis;
- e) the Company is not a Listed Company hence this clause is not applicable to the Company;
- f) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

37. Frauds reported by the Auditors

No fraud has been reported by the Auditors of the Company under Section 143(12) of the Companies Act, 2013.

38. Acknowledgement

Your Directors would like to express their sincere appreciation for the assistance and co-operation received from the financial institutions, Government Authorities, customers, vendors and members during the year under review. Your directors also wish to place on record their deep sense of appreciation for the committed services by the Company's executives, staff and workers.

**For and on behalf of the Board of Directors
For Biodeal Pharmaceuticals Private Limited**

Place: Nalagarh
Date: 25.08.2022


Anurag Kumar
Director
DIN:08598700
Address: House No 793,
Sector 3-d, Bokaro Steel City,
Bokaro, Jharkhand-827001


Dev Datt
Whole-time Director
DIN:09129131
Address: BG-5A/6-C, Paschim
Vihar, New Delhi- 110063



Annexure III

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto.

1. Details of contracts or arrangements or transactions not at arm's length basis

(a) Name(s) of the related party and nature of relationship	NA
(b) Nature of contracts/arrangements/transactions	NA
(c) Duration of the contracts / arrangements/transactions	NA
(d) Salient terms of the contracts or arrangements or transactions including the value, if any	NA
(e) Justification for entering into such contracts or arrangements or transactions	NA
(f) date(s) of approval by the Board	NA
(g) Amount paid as advances, if any:	NA
(h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188	NA


2. Details of material contracts or arrangement or transactions at arm's length basis

S. No	Name(s) of the related party and nature of relationship	Nature of contracts/arrangements/transactions	Duration of the contract s/arrangements/transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Amount For the Year ended March 31, 2022	Date(s) of approval by the Board, if any:	Amount paid as advanced if any:
1.	Anurag Kumar (Director)	Director Remuneration	5 Years	Remuneration to Director	60,00,000/-	15/04/2021	NIL
2.	DevDatt (Whole-time Director)	Director Remuneration	5 Years	Remuneration to Director	12,00,000/-	15/04/2021	NIL
3	Padma	Salary	On-going	Remuneration	12,00,000/-	15/04/2021	20,55,000/-

	Sharma (Relative of Director)			to relative of Director			
4	Anchal Kumari (Relative of Director)	Salary	On-going	Remuneration to relative of Director	1,50,000/-	15/04/2021	NIL
5	Gunjan Kumar (Relative of Director)	Salary	On-going	Remuneration to relative of Director	18,00,000/-	15/04/2021	NIL
6	Atlantas Worldwide Pvt Ltd (Relative Of Director Is Director)	Freight Charges	On-going	Freight Charges Paid	1,25,91,647/-	15/04/2021	NIL
7	Lobster Overseas (Proprietor is Relative of Director)	Purchase and Sale of Goods	NA	In the Ordinary Course of Business	2,22,26,710/-	15/04/2021	NIL
8	Xenone Healthcare Pvt Ltd (Relative of Director is Director)	Sale Of Goods	NA	In the Ordinary Course of Business	77,36,280	15/04/2021	NIL

**For and on behalf of the Board of Directors
For Biodeal Pharmaceuticals Private Limited**

Place: Nalagarh
Date: 25.08.2022

Anurag Kumar 
Director
DIN:08598700
Address: House No 793,
Sector 3-d, Bokaro Steel City,
Bokora, Jharkhand-827001


DevDatt
Whole-time Director
DIN:09129131
Address: BG-5A/6-C, Paschim
Vihar, New Delhi- 110063